Who is sponsoring NCT05934929?

NCT05934929 is sponsored by Centre Henri Becquerel.

What drugs are being tested in NCT05934929?

Interventions in NCT05934929: Circulating tumor DNA detection.

What condition does NCT05934929 study?

NCT05934929 studies Squamous Cell Carcinoma of the Oral Cavity.

Is NCT05934929 still recruiting?

NCT05934929 is currently active, enrolled. Last updated 2 January 2026.

Last reviewed 2026-01-02 · How we verify

NCT05934929: MARGINS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Contribution of Residual Tumour DNA Testing on the Surgical Bed

Active, enrolled NA Last updated 2 January 2026

What this trial tests

NA trial testing Circulating tumor DNA detection in Squamous Cell Carcinoma of the Oral Cavity in 31 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 January 2024

Primary endpoint
22 December 2025

29 December 2027

Quick facts

Lead sponsor	Centre Henri Becquerel
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	31
Start date	8 January 2024
Primary completion	22 December 2025
Estimated completion	29 December 2027
Sites	2 locations across France

Drugs / interventions tested

Circulating tumor DNA detection

Conditions studied

Squamous Cell Carcinoma of the Oral Cavity — all drugs for Squamous Cell Carcinoma of the Oral Cavity →

Sponsor

Centre Henri Becquerel — full company profile →

Who can join

18 and older, any sex, with Squamous Cell Carcinoma of the Oral Cavity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the interest of residual tumour DNA research in the operating bed after squamous cell carcinoma excision.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Squamous Cell Carcinoma of the Oral Cavity

Currently open trials in the same condition.

NCT04191460 — Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer · Phase 2 · recruiting

Other Centre Henri Becquerel trials

Trials by the same sponsor.

NCT07499765 — Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis · NA · not yet recruiting
NCT07259915 — Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck · NA · not yet recruiting
NCT07285564 — Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer · NA · recruiting
NCT07190755 — Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinom · NA · recruiting
NCT07029100 — Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05934929 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Henri Becquerel
Last refreshed: 2 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05934929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing